anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,130,144. Toiletry and pharmaceutical compositions. GENERAL ANILINE & FILM CORP. 30 Dec., 1965 [5 Jan., 1965], No. 55215/65. Heading A5B. [Also in Divisions C3 and C5] A toiletry or pharmaceutical composition for application to skin or appendages of the skin e.g. hair and nails comprises a dermatologically acceptable carrier and an emollient polymer of a heterocyclic N-vinyl monomer containing a group in the ring, in which polymer at least 25% of the monomeric units are alkylated with an alkyl or halogenated alkyl group or chain of at least 10 carbon atoms, the halogenated alkyl group or chain being chloroalkyl, fluoralkyl or chlorofluoralkyl. Exemplified compositions relate to cold cream, brushless shaving cream, hand lotion, vanishing cream, cleansing cream, emollient cream, quick-liquefying cream, paste rouge, lipstick, anti-perspirant stick, synthetic soap bar, sunscreen lotion, hair shampoo, nail polish remover, cuticle softener, bath talc, after-shave lotion, hair spray, hair-groom, hand cleaner and dentifrice. The usual carrier materials and other ingredients are also included in the exemplified compositions. The polymers may be used in pharmaceutical compositions for external use e.g. salves, ointments and suppositories containing conventional antiseptic, germicidal and medicinal agents and are particularly useful in ammoniated mercury ointment and compositions for the treatment of burns and haemorrhoids.
Murine sickle cell disease (SCD) results in damage to multiple organs, likely mediated first by vasculopathy. While the mechanisms inducing vascular damage remain to be determined, nitric oxide bioavailability and sterile inflammation are both considered to play major roles in vasculopathy. Here, we investigate the effects of high mobility group box-1 (HMGB1), a pro-inflammatory damage-associated molecular pattern (DAMP) molecule on endothelial-dependent vasodilation and lung morphometrics, a structural index of damage in sickle (SS) mice. SS mice were treated with either phosphate-buffered saline (PBS), hE-HMGB1-BP, an hE dual-domain peptide that binds and removes HMGB1 from the circulation via the liver, 1-[4-(aminocarbonyl)-2-methylphenyl]-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrole-2-propanoic acid (N6022) or N-acetyl-lysyltyrosylcysteine amide (KYC) for three weeks. Human umbilical vein endothelial cells (HUVEC) were treated with recombinant HMGB1 (r-HMGB1), which increases S-nitrosoglutathione reductase (GSNOR) expression by ∼80%, demonstrating a direct effect of HMGB1 to increase GSNOR. Treatment of SS mice with hE-HMGB1-BP reduced plasma HMGB1 in SS mice to control levels and reduced GSNOR expression in facialis arteries isolated from SS mice by ∼20%. These changes were associated with improved endothelial-dependent vasodilation. Treatment of SS mice with N6022 also improved vasodilation in SS mice suggesting that targeting GSNOR also improves vasodilation. SCD decreased protein nitrosothiols (SNOs) and radial alveolar counts (RAC) and increased GSNOR expression and mean linear intercepts (MLI) in lungs from SS mice. The marked changes in pulmonary morphometrics and GSNOR expression throughout the lung parenchyma in SS mice were improved by treating with either hE-HMGB1-BP or KYC. These data demonstrate that murine SCD induces vasculopathy and chronic lung disease by an HMGB1- and GSNOR-dependent mechanism and suggest that HMGB1 and GSNOR might be effective therapeutic targets for reducing vasculopathy and chronic lung disease in humans with SCD.
A method and apparatus is described for optically scanning a field of view, the field of view including at least part of an organ as exposed during surgery, and for identifying and classifying areas of tumor within the field of view. The apparatus obtains a spectrum at each pixel of the field of view, and classifies pixels with a kNN-type or neural network classifier previously trained on samples of tumor and organ classified by a pathologist. Embodiments use statistical parameters extracted from each pixel and neighboring pixels. Results are displayed as a color-encoded map of tissue types to the surgeon. In variations, the apparatus provides light at one or more fluorescence stimulus wavelengths and measures the fluorescence light spectrum emitted from tissue corresponding to each stimulus wavelength. The measured emitted fluorescence light spectra are further used by the classifier to identify tissue types in the field of view.
The invention relates to a Chinese herbal preparation for treating ankylosing spondylitis, which comprises the following Chinese medicinal herbs by weight: 10g of rhizoma cibotii, 15g of pilose antler, 10g of himalayan teasel root, 5g of scorpio, 15g of kudzu vine root, 12g of chuanxiong rhizome, 5g of caulis spatholobi, 15g of white paeony root, 15g of common peony root, 10g of safflower carthamus, 15g of medicinal cyathula root and 10g of white mustard seed. The Chinese herbal preparation is prepared by using the steps of: weighing the Chinese medicinal herbs in the formula, adding 1500ml of water, decocting with slow fire to ensure that medicine liquid is concentrated to 250ml, filtering dregs of a decoction and preparing a decoction. During the treatment, the decoction is taken orally, each dosage is taken every day, and one treatment course includes 90 days. The Chinese herbal preparation is used for treating the ankylosing spondylitis through improving immunity and micro circulation and eliminating blood micro coagulation. The Chinese herbal preparation has the functions of inhabiting fibrosis and ossification, inhibiting or repairing bone destruction and the like, and achieves the purposes of releasing symptoms and inhibiting the disease progressing from multiple aspects and multiple links. The Chinese herbal preparation has the advantages of low cost and no toxic and side effects.
Participants in this arm will receive the standard care for managing allergic rhinitis, which includes regular clinical evaluations and treatments as determined by their healthcare provider. In addition, they will be provided access to the QHSLab digital platform, which includes the Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS) tools. These tools will offer continuous symptom monitoring, medication reminders, and personalized feedback based on patient-reported data. The intervention aims to improve symptom management, medication adherence, and quality of life over the 12-month follow-up period.
To provide an aerosol product which is highly safe against fire, causes little fluttering down on an injection object and freezes an injected object.SOLUTION: An aerosol product comprises: a container body filled with an aerosol composition formed of an aqueous stock solution and liquid gas; and an aerosol valve attached to the container body. A content of the aqueous stock solution is 10-40 mass% in the aerosol composition. A content of the liquid gas is 60-90 mass% in the aerosol composition. The liquid gas contains hydrofluoro-olefin and dimethyl ether. The aerosol valve comprises: a gas phase introduction hole for introducing a gas phase component in the aerosol composition into a housing; and a liquid phase introduction hole for introducing a liquid phase component in the aerosol composition to the housing. The aerosol product is configured so that an injected object freezes.SELECTED DRAWING: None
Patients receive iberdomide orally on days 1-21 and 29-49, belantamab mafodotin IV on day 1, and dexamethasone PO on days 1, 8, 15, 22, 29, 36, 43, and 50 of each cycle. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening as clinically indicated and CT, MRI and/or PET scans during screening and as clinically indicated on study. Patients also undergo a bone marrow biopsy and aspiration and blood sample collection throughout trial.
In some embodiments, methods, systems, software and uses are provided for synchronizing medical images displays. An input identifying a region of interest in a first medical image is received. A second region of interest in a second medical image is determined based the first region. The first medical image and a first indication of the first region are displayed in a first viewport of a GUI. The second medical image and a second indication of the second region are displayed in a second viewport of the GUI. A display adjustment input is received to adjust the displaying of one of the first or second region of interest. Based on the display adjustment input and the correspondence information, an adjustment of the displaying of the first region of interest in the first viewport and an adjustment of the displaying of the second region of interest in the second viewport is implemented.
Current evidence based psychiatric treatment for child, adolescent, and young adult anxiety disorders involves a trial and error process. Pediatric psychiatrists start with the first line treatments (i.e. SSRI or psychotherapy), which requires from 4-8 weeks to work. There is a long interval between treatment initiation and response with only 50 to 60% likelihood that the treatment chosen will succeed in reducing anxiety symptoms. The science that will enable us to predict who will respond to medication treatment does not exist. Studies have demonstrated a correlation between cellular markers in white blood cells and psychiatric disorders suggesting that certain genes may also change their expression in peripheral cells in response to treatment of psychiatric disorders. Several studies report a significant decrease in expression of key genes that are involved in the pathophysiology of anxiety and depression in the brain, such as BDNF, CREB and HDAC5 levels in leukocytes of people with mood and anxiety disorders. The levels of BDNF, HDAC5 and CREB in white blood cells then respond to treatment and match that of controls after treatment with SSRIs. The increased accessibility to sequencing technology allows us to survey many more potential biomarkers than what was possible just several years ago. This may enable us to formulate a test that will predict, based on biocellular markers, treatment outcome in anxiety disorders for children, adolescents, and young adults before the onset of treatment. By finding molecular markers that can predict treatment success from the onset, the investigators can improve treatment outcomes considerably compared to current standard treatment practices. This kind of personalized medicine is the future of psychiatry.
1. Trial Design： This is a multi-center, randomized, double-blind, placebo-controlled phase III study，which plans to enroll 428 participants who will be randomized to Shenqi Sherong pill group or placebo control group. The Modified Japanese Orthopaedic Association (mJOA) Score combined with the changes of clinical symptoms and syndrome score are used as the validity index. The laboratory examination and incidence of adverse events are used as the safety index.
2. Therapeutic schedule： Participants will be provided with neck braces and recommended to wear them daily or outdoors along with health education. Participants will be treated with the investigational drug (Shenqi Sherong Pill or placebo ) by taking two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks, with a 2-week follow-up after withdrawal.
Folic Acid: Allergic sensitizations has been reported following both oral and parenteral administration of folic acid.

  
Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving  Dexatran™ after meals may control occasional gastrointestinal disturbances.  Dexatran™ is best absorbed when taken at bedtime. 

Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in some patients.
BACKGROUND: Acceptance and Commitment Therapy (ACT) is a type of Cognitive Behavioural Therapy, which has demonstrated positive outcomes in individuals with chronic pain. The purpose of this study was to compare the effect of an 8-week programme combining Exercise with Acceptance and Commitment Therapy (ExACT) with a standalone supervised exercise programme at 1-year follow-up.
METHODS: One hundred and seventy-five people with chronic pain were randomly assigned to ExACT or supervised exercise only. The primary outcome was pain interference measured with the Brief Pain Inventory-Interference Scale. Secondary and treatment process outcomes included pain severity, depression, anxiety, pain catastrophizing, pain self-efficacy, fear avoidance, pain acceptance, committed action, healthcare utilization, patient satisfaction, and global impression of change. Estimates of treatment effects at 1-year follow-up were based on intention-to-treat analyses, implemented using a linear mixed-effects model.
RESULTS: Eighty-three participants (47.4%) returned the outcome measures at 1-year follow-up. No significant difference was observed between the groups for the primary outcome, pain interference. There was a statistically significant difference between the groups, in favour of ExACT for pain catastrophizing. Within group improvements that were observed within both groups at earlier timepoints were maintained at 1-year follow-up for many of the secondary and treatment process outcomes. ExACT group participants reported higher levels of satisfaction with treatment and global perceived change.
CONCLUSIONS: The study results showed no significant difference between the two groups for the primary outcome pain interference at 1-year follow-up. Future research could investigate factors that may predict and optimize outcomes from these types of intervention for people living with chronic pain.
SIGNIFICANCE: Few previous randomized controlled trials investigating ACT for chronic pain have included long-term follow-up. This study found that Exercise combined with ACT was not superior to supervised exercise alone for reducing pain interference at 1-year follow-up. Further research is necessary to identify key processes of therapeutic change and to explore how interventions may be modified to enhance clinical outcomes for people with chronic pain.
The literature regarding the role of probiotics in critically ill patients who have undergone mechanical ventilation (MV) is unclear; therefore, this umbrella systematic review and meta-analysis was carried out to clarify the effects of probiotics on the clinical outcomes of mechanically ventilated patients. The Scopus, PubMed/Medline, ISI Web of Science, and Google Scholar online databases were searched up to February 2023. All meta-analyses evaluating the impact of probiotics in patients under MV were considered eligible. The assessment of multiple systematic reviews (AMSTAR) questionnaire was used to evaluate the quality of the studies. Data were pooled using the random-effects approach. Thirty meta-analyses and nine clinical outcomes were re-analyzed. Probiotics significantly decreased ventilator-associated pneumonia (VAP) incidence, nosocomial infections, intensive care unit (ICU) length of stay, hospital length of stay, ICU mortality, hospital mortality, MV duration, duration of antibiotic use, and diarrhea. The obtained results of the current umbrella meta-analysis indicate that probiotic administration could be considered an adjunct therapy for critically ill patients; however, no specific probiotic treatment regimen can be recommended due to the diverse probiotics used in the included meta-analyses. The following microorganisms were used at various doses and combinations throughout the studies: Lacticaseibacillus casei, Lactiplantibacillus plantarum, L. acidophilus, L. delbrueckii, L. bulgaricus, Bifidobacterium longum, B. breve, B. salivarius, Pediococcus pentosaceus, Lactococcus raffinolactis, B. infantis, B. bifidum, Streptococcus thermophilus, Ligilactobacillus salivarius, L. lactis, B. lactis, Saccharomyces boulardii, L. rhamnosus GG, L. johnsonii, L. casei, S. faecalis, Clostridium butyricum, Bacillus mesentericus, L. sporogenes, S. boulardii, L. paracasei, B. subtilis, and Enterococcus faecium.
Within 30 seconds after the 0° position measurement completion, the subjects were transferred to the 30° position and rested for 15 minutes under the 30° position. In other words, a washout period of 15 minutes was established between two measurements to ensure the stability of vital signs and avoid confounding effects. The blood pressure, heart rate, and blood flow velocity of the middle cerebral artery were measured again for 5 minutes after the vital signs were stable.
The safety and efficacy of caspofungin were evaluated in pediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials. 

The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomized, double-blind study comparing caspofungin (50 mg/m2 IV once daily following a 70 mg/m2 loading dose on Day 1 [not to exceed 70 mg daily]) to AmBisome (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on AmBisome) as empirical therapy in pediatric patients with persistent fever and neutropenia. The study design and criteria for efficacy assessment were similar to the study in adult patients [see Clinical Studies (14.1)]. Patients were stratified based on risk category (high-risk patients had undergone allogeneic stem cell transplantation or had relapsed acute leukemia). Twenty-seven percent of patients in both treatment groups were high risk. Favorable overall response rates of pediatric patients with persistent fever and neutropenia are presented in Table 15. 

The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in pediatric patients (ages 3 months to 17 years) with candidemia and other Candida infections, esophageal candidiasis, and invasive aspergillosis (as salvage therapy). The study employed diagnostic criteria which were based on established EORTC/MSG criteria of proven or probable infection; these criteria were similar to those criteria employed in the adult studies for these various indications. Similarly, the efficacy time points and endpoints used in this study were similar to those employed in the corresponding adult studies [see Clinical Studies (14.2, 14.3,  and  14.4)]. All patients received caspofungin at 50 mg/m2 IV once daily following a 70 mg/m2 loading dose on Day 1 (not to exceed 70 mg daily). Among the 49 enrolled patients who received caspofungin, 48 were included in the efficacy analysis (one patient excluded due to not having a baseline Aspergillus or Candida infection). Of these 48 patients, 37 had candidemia or other Candida infections, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis. Most candidemia and other Candida infections were caused by C. albicans (35%), followed by C. parapsilosis (22%), C. tropicalis (14%), and C. glabrata (11%). The favorable response rate, by indication, at the end of caspofungin therapy was as follows: 30/37 (81%) in candidemia or other Candida infections, 5/10 (50%) in invasive aspergillosis, and 1/1 in esophageal candidiasis.
Patients receive canakinumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention is concerned with a method of monitoring a use cycle or delivery process including at least a first and a second dispense event performed by means of a variable-dose delivery device. The method comprises, by an electronic unit associated with the delivery device, determining, during the use cycle, first and second event details of the first and second dispense event, respectively. The dispense event details include at least one of a start, end, or other time of the dispense event, a dispense dose dispensed during the dispense event, and a device orientation of the device during the dispense event. The method comprises determining, at the end of the use cycle, cycle properties including at least one of a number of dispense events in the use-cycle and a holding time status indicative of a regular holding time having been observed at the end of the use cycle. The method comprises evaluating, after the use cycle, an injection criteria to derive an injection, or non-priming, score of the second event, indicative of a probability that the second dispense dose has been injected into the target tissue and was not a priming or air shot. The injection criteria either is a multi-event-criteria based on an event detail of the first event, or a cycle criteria based on a cycle property of the use cycle. The method comprises determining and forwarding a cycle dispense dose based on the injection score, in particular a cycle injection dose disregarding any event dispense dose of a dispense event with a low or insufficient injection score.
A fundamental challenge in neuroscience is accurately defining brain states and predicting how and where to perturb the brain to force a transition. Here, we investigated resting-state fMRI data of patients suffering from disorders of consciousness (DoC) after coma (minimally conscious and unresponsive wakefulness states) and healthy controls. We applied model-free and model-based approaches to help elucidate the underlying brain mechanisms of patients with DoC. The model-free approach allowed us to characterize brain states in DoC and healthy controls as a probabilistic metastable substate (PMS) space. The PMS of each group was defined by a repertoire of unique patterns (i.e., metastable substates) with different probabilities of occurrence. In the model-based approach, we adjusted the PMS of each DoC group to a causal whole-brain model. This allowed us to explore optimal strategies for promoting transitions by applying off-line in silico probing. Furthermore, this approach enabled us to evaluate the impact of local perturbations in terms of their global effects and sensitivity to stimulation, which is a model-based biomarker providing a deeper understanding of the mechanisms underlying DoC. Our results show that transitions were obtained in a synchronous protocol, in which the somatomotor network, thalamus, precuneus and insula were the most sensitive areas to perturbation. This motivates further work to continue understanding brain function and treatments of disorders of consciousness.
The participants will participate in cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total. Recommendations for individualized exercise prescription and lifestyle modification will be given to the participants as well.
Participants who do not fulfill any of discontinuation criteria will be randomized to 1 of 2 Treatments (Treatment A or B) on Day 1. Treatment A: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus placebo propranolol once daily from Day 1 to Day 19; Treatment B: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus 80 mg propranolol once daily from Day 1 to Day 19.